AstraZeneca (LON:AZN) Rating Reiterated by Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZNGet Rating)‘s stock had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft in a report released on Tuesday, Digital Look reports. They presently have a £115 ($143.66) price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of 8.96% from the stock’s current price.

Several other analysts also recently issued reports on AZN. UBS Group set a £105 ($131.17) target price on shares of AstraZeneca in a research note on Monday, March 7th. Deutsche Bank Rese… set a £115 ($143.66) price objective on AstraZeneca in a research note on Wednesday, April 6th. The Goldman Sachs Group set a GBX 6,950 ($86.82) price objective on AstraZeneca in a research report on Friday. JPMorgan Chase & Co. set a £120 ($149.91) target price on AstraZeneca in a report on Tuesday. Finally, Barclays restated an “overweight” rating and set a £120 ($149.91) price target on shares of AstraZeneca in a report on Friday. Two investment analysts have rated the stock with a sell rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of £104.75 ($130.85).

AZN stock opened at £105.54 ($131.84) on Tuesday. The company has a debt-to-equity ratio of 82.58, a current ratio of 1.16 and a quick ratio of 0.67. The firm has a market capitalization of £163.53 billion and a P/E ratio of 1,675.24. AstraZeneca has a 52-week low of GBX 7,556 ($94.39) and a 52-week high of £110 ($137.41). The company’s 50 day simple moving average is GBX 9,866.64 and its 200-day simple moving average is GBX 9,075.91.

AstraZeneca Company Profile (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Articles

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.